Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 7/20 | 0.49 |
| ▸ | AURKA | O14965 | 8/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965030 | 0.94 | AURKA (0.53) | MAPK7AURKAAURKB | |
| SCHEMBL4962333 | 0.92 | MAPK7 (0.48) | MAPK7AURKAAURKB | |
| SCHEMBL4966697 | 0.92 | AURKA (0.53) | MAPK7AURKAAURKBCHEK1 | |
| SCHEMBL5075226 | 0.92 | AURKA (0.52) | MAPK7AURKAAURKB | |
| SCHEMBL5604236 | 0.91 | AURKA (0.53) | MAPK7AURKAAURKB | |
| SCHEMBL4963778 | 0.90 | AURKA (0.52) | MAPK7AURKAAURKB | |
| SCHEMBL4962787 | 0.89 | MAPK7 (0.46) | MAPK7AURKAAURKBCHEK1 | |
| SCHEMBL4964964 | 0.89 | CHEK1 (0.54) | MAPK7AURKAAURKBCHEK1 | |
| SCHEMBL4964717 | 0.89 | CHEK1 (0.48) | MAPK7AURKAAURKBCHEK1 | |
| SCHEMBL4966483 | 0.89 | MAPK7 (0.50) | MAPK7AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| EP-1893214-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1893598-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006135629-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135721-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | FLT3, KIT, NTRK2 | MAPK7 489/4885AURKA 94/4885AURKB 44/4885 |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | FLT3, MCL1, CDC42BPG | MAPK7 957/4885AURKA 174/4885AURKB 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.